By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Ophthotech Corporation 

One Penn Plaza
Suite 1924
New York  New York  10119  U.S.A.
Phone: 212-845-8200 Fax: 212-845-8250


SEARCH JOBS

Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech's most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech's second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD, and in combination with anti-VEGF therapy in wet AMD patients.


Key Statistics


Email: n/a
Ownership: Public

Web Site: Ophthotech
Employees:
Symbol: OPHT
 









Company News
Ophthotech (OPHT) Reports Third Quarter 2016 Financial And Operating Results 11/8/2016 8:20:38 AM
Ophthotech (OPHT) Announces The Publication Of Fovista In Combination With Lucentis Phase 2b Study Results In Ophthalmology, The Journal Of The American Academy of Ophthalmology 10/31/2016 12:04:40 PM
Ophthotech (OPHT) To Report Third Quarter 2016 Financial Results And Host Conference Call On Tuesday, November 8, 2016 10/24/2016 10:45:13 AM
Why Ophthotech (OPHT) Is Trading Down On Regeneron (REGN)'s News 10/3/2016 7:28:45 AM
Ophthotech Corporation (OPHT) To Present At The Morgan Stanley Global Healthcare Conference 9/6/2016 11:25:45 AM
Ophthotech Corporation (OPHT) Reports Second Quarter 2016 Financial And Operating Results 8/3/2016 11:05:09 AM
Ophthotech Corporation (OPHT) Announces Election Of Ian F. Smith, Vertex (VRTX) Executive Vice President And Chief Financial Officer, To Its Board Of Directors 8/2/2016 11:22:18 AM
Ophthotech Corporation (OPHT) To Report Second Quarter 2016 Financial Results And Host Conference Call On Wednesday, August 3, 2016 7/25/2016 9:28:04 AM
Ophthotech Corporation (OPHT) Completes Patient Recruitment In Phase 3 Trial Of Fovista Anti-PDGF Therapy In Combination With Eylea Or Avastin In Wet Age-Related Macular Degeneration 6/20/2016 11:50:22 AM
Ophthotech Corporation (OPHT) To Present At The Goldman, Sachs & Co. 37th Annual Global Healthcare Conference 5/31/2016 10:41:25 AM
123456789
//-->